Business Context and Reporting Period
Company: Bausch Health Companies Inc.
Filing Type: Form 8-K (Current Report)
Date: November 24, 2025
Event: Commencement of exchange offers for outstanding senior secured notes.
Key Financial Metrics and Transaction Details
This filing details a debt restructuring transaction rather than operational financial results. Key metrics include:
- Maximum New Notes Amount: Up to $1.6 billion aggregate principal amount.
- New Instrument: 10.00% Senior Secured Notes due 2032.
- Existing Instruments Targeted:
- 4.875% Senior Secured Notes due 2028.
- 11.00% Senior Secured Notes due 2028.
- Existing 10.00% Notes (2032): $4.4 billion principal amount outstanding (issued April 2025).
- Participating Holders Commitment: Approximately $1,545 million (46% of outstanding existing notes).
Material Changes and Transaction Structure
The Company is exchanging higher-cost or shorter-duration debt for new 10.00% notes due 2032. Material structural elements include:
- Target Ratio: The Company expects to accept 52.6% of the 11.00% Notes and 47.4% of the 4.875% Notes of the total accepted amount, subject to adjustments.
- Fungibility: New Notes will be treated as a single series with the existing $4.4 billion 10.00% Notes due 2032.
- Support Agreement: A Transaction Support Agreement has been signed with holders representing 46% of the outstanding debt, including 39% of the 4.875% Notes and 52% of the 11.00% Notes.
- Prioritization: Notes tendered prior to the "Early Tender Time" are prioritized over those tendered later.
Guidance, Risks, and Contingencies
Management Commentary: The filing indicates a strategic move to consolidate debt maturities and interest rates under a single series of 10.00% notes due 2032. The transaction is subject to conditions specified in the confidential Exchange Offer Memorandum.
Risks and Contingencies:
- Regulatory Compliance: The offer is restricted to Qualified Institutional Buyers (Rule 144A) and non-U.S. persons (Regulation S). The New Notes are not registered under the Securities Act.
- Transaction Failure: If the Target Ratio cannot be met or the Maximum Notes Amount is not reached, the Company may adjust acceptance or fail to issue the full $1.6 billion.
- Covenants: The Transaction Support Agreement includes covenants that may limit the Offerors' rights regarding the Offers.
Investor Verification Checklist
- Verify the final acceptance ratio of the 4.875% vs. 11.00% Notes once the offer expires.
- Confirm the total principal amount of New Notes actually issued versus the $1.6 billion maximum.
- Review the confidential Exchange Offer Memorandum for specific conditions precedent to closing.
- Assess the impact of the new 10.00% interest rate on future cash flow obligations compared to the blended rate of the existing notes.
- Monitor for any regulatory challenges regarding the unregistered status of the New Notes in the U.S. and Canada.